ONCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Oncorus's change in receivables for the quarter that ended in Mar. 2023 was $0.00 Mil. It means Oncorus's Accounts Receivable stayed the same from Dec. 2022 to Mar. 2023 .
Oncorus's change in receivables for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Oncorus's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .
Oncorus's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oncorus's liquidation value for the three months ended in Mar. 2023 was $-33.65 Mil.
The historical data trend for Oncorus's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncorus Annual Data | |||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||
Change In Receivables | - | - | - | - | - |
Oncorus Quarterly Data | |||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncorus (OTCPK:ONCR) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Oncorus's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Oncorus's accounts receivable are only considered to be worth 75% of book value:
Oncorus's liquidation value for the quarter that ended in Mar. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 44.982 | - | 78.632 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -33.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Oncorus's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian J. Shea | officer: Interim CEO | C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810 |
Alexander Nolte | officer: Interim CFO | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
James E Flynn | director, 10 percent owner, other: *Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Douglas Fambrough | director | C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
Rick Wanstall | officer: CFO and Treasurer | C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472 |
Stephen Harbin | officer: COO and Chief of Staff | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Barbara Yanni | director | 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
Eric Rubin | director | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Christophe Queva | officer: CSO and SVP, Research | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Scott A Canute | director | FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Mpm Bioventures 2014, L.p. | 10 percent owner | C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Luke Evnin | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
Oncology Impact Fund (cayman) Management L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Mpm Asset Management Investors Sunstates Fund Llc | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Ansbert Gadicke | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-30-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
By sperokesalga sperokesalga • 03-24-2023
By Value_Insider Value_Insider • 11-18-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 05-17-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By Value_Insider Value_Insider • 11-02-2022
By GuruFocusNews GuruFocusNews • 07-03-2022
By GuruFocusNews GuruFocusNews • 06-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.